not tagged
adaptimmune therapeutics
['urothelial', 'headandneck', 'ovarian', '$adap']
$adap updates on progress with 2nd gen tcr t cells. response rate in 25 subjects with #ovarian, #urothelial, and #headandneckcancer cancers, of 44%. present trial to be seen for signal finding: #esmo22
Natural born biotech stock trader/investor. Trained in RNAi. 

Not investment advice